contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bergenbio-asa-approval-of-the-merger-plan-and-the-fully-underwritten-rights-issue

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Oncoinvent is a clinical phase radiopharmaceutical company developing treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver radiation directly to cancer cells. The Company's product candidate, Radspherin®, is an alpha radiation therapy candidate designed for the local treatment of cancer that has spread to body cavities. Oncoinvent has its headquarters in Oslo.

Oncoinvent

Bergen, 4 August 2025: Reference is made to the joint stock exchange announcement made on 30 June 2025 by BerGenBio ASA (the "Company") and Oncoinvent ASA ("Oncoinvent") regarding the contemplated...

Bergen, 4 August 2025: Reference is made to the joint stock exchange announcement made on 30 June 2025 by BerGenBio ASA (the "Company") and Oncoinvent ASA ("Oncoinvent") regarding the contemplated combination of the Company, Oncoinvent and BerGenBio Norge AS though a statutory triangular merger (the "Merger"). An extraordinary general meeting of the Company was held on 12:00 hours (CEST) today by electronic means through Lumi AGM. All items on the agenda were resolved in accordance with the board of directors' and the nomination committee's proposals, including, but not limited to, approval of the merger plan dated 30 June 2025 (the "Merger Plan") and the fully underwritten rights issue in the Company to raise gross proceeds of NOK 130 million. As announced by Oncoinvent today, the Merger Plan has been approved by the extraordinary general meeting of Oncoinvent. As a consequence, the decision to approve the Merger will now be filed with the Norwegian Register of Business Enterprises. Completion of the Merger remains subject to customary terms and conditions, as further described in the Merger Plan and the joint stock exchange announcement made on 30 June 2025.The minutes from the extraordinary general meeting are attached hereto and will also be made available on the Company's website <a href="http://www.bergenbio.no">www.bergenbio.no</a>. For further information regarding the Merger and the complete terms and conditions for the Merger, please see the Merger Plan with appendices available on <a href="http://www.bergenbio.no">www.bergenbio.no</a>. For further information, please contact: Olav Hellebø, CEO, BerGenBio ASA, <a href="mailto:ir@bergenbio.com">ir@bergenbio.com</a>Rune Skeie, CFO, BerGenBio ASA, <a href="mailto:rune.skeie@bergenbio.com">rune.skeie@bergenbio.com</a>This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. &nbsp;<div></div>

BerGenBio ASA: Approval of the merger plan and the fully underwritten rights issue